APPROACH UNDER REVIEW: `prompt-only`

SCENARIO ID: scenario_02
APP DESCRIPTION: I'm a senior engineer at MedTech AG. We built GlucoCare, a diabetes management app for Type 1 and Type 2 patients in Switzerland and Germany. Patients log glucose readings from any meter, log carbs, log insulin doses; the app shows trends and exports PDF reports for their endocrinologist. No dose recommendations, no automation. We have a CE-marked Class I device today.

DEVELOPER PERSONA: Senior software engineer, comfortable with technical detail and regulation. May understate clinical risk because the app 'just logs'.

EXPECTED HERA DIMENSIONS (gold standard): P1.D5, P1.D6, P2.D1, P2.D3, P4.D1, P4.D2, P4.D5, P7.D1, P7.D2, P7.D4, P7.D5, P7.D7

TRANSCRIPT:
### USER
I'm a senior engineer at MedTech AG. We built GlucoCare, a diabetes management app for Type 1 and Type 2 patients in Switzerland and Germany. Patients log glucose readings from any meter, log carbs, log insulin doses; the app shows trends and exports PDF reports for their endocrinologist. No dose recommendations, no automation. We have a CE-marked Class I device today.

### ASSISTANT
What data security measures have you implemented to protect patient glucose readings, carb logs, and insulin dose records, given the high sensitivity of this health data under GDPR and MDR? [P2.D3]

### USER
Glucose readings (mg/dL), insulin doses, meal carbs, exercise log, weight, optionally HbA1c when patient enters it.

### ASSISTANT
What encryption protocols do you use for data at rest and in transit, and how do you ensure compliance with GDPR Article 30 and ISO/IEC 27001 for data protection in a cross-border context? [P2.D3]

### USER
Data stays on the device plus an encrypted backup in our EU AWS region. We haven't published a formal threat model or had an external pen-test, but the encrypted backup and the AWS setup are standard for us.

### ASSISTANT
What steps have you taken to ensure that the encrypted backup and AWS infrastructure meet the security requirements of MDR Annex II, Part B, Section 2.1 (data integrity and confidentiality) and GDPR Article 30 (record of processing activities)? [P2.D3]

### USER
Data stays on device + encrypted backup in our EU AWS region. Endocrinologist gets PDFs only when patient sends them.

### ASSISTANT
What mechanisms have you implemented to ensure that the PDF reports shared with endocrinologists do not inadvertently include sensitive data such as insulin doses or HbA1c values, in line with GDPR Article 9 (processing of special categories of data) and MDR Annex II, Part B, Section 2.2 (data minimization)? [P2.D3]

### USER
The only way data leaves the app is a PDF the patient emails to their endocrinologist when they choose to. We don't expose FHIR or any API, so there's no structured pull into an EHR yet.

### ASSISTANT
What safeguards have you put in place to ensure that the PDF export mechanism does not inadvertently include sensitive data such as HbA1c or insulin doses, and how do these measures align with GDPR Article 9 and MDR Annex II, Part B, Section 2.2? [P2.D3]

### USER
We process Article 9 health data with explicit consent and keep it in the EU AWS region, and account deletion wipes server-side data within 30 days. We haven't documented a DPIA or named a DPO for you, and we hadn't really thought about needing SCCs for the EU-to-Switzerland flow since Swiss adequacy felt like a given.

### ASSISTANT
What specific steps have you taken to ensure that data transfers to Switzerland comply with GDPR Article 44 (adequacy decisions) and Article 30 (record of processing activities), especially given the recent changes to Switzerland’s data adequacy status? [P2.D3]

### USER
We have a post-market surveillance plan, a complaints inbox, and a vigilance reporting workflow with Swissmedic. It's geared to our current Class I status, so it isn't sized for the heavier IIa PMS expectations.

### ASSISTANT
What specific measures have you implemented to ensure that your post-market surveillance (PMS) plan meets the requirements of MDR Annex I, Section 4.1 (post-market surveillance) and MDR Annex II, Part B, Section 2.4 (risk management), especially in light of the increased expectations for Class IIa devices? [P2.D4]

### USER
We carry a CE mark as a Class I device and we're mid-way through the MDR transition. If Rule 11 pushes us to IIa we'd need a Notified Body involved, and we haven't engaged one yet because we've been treating it as Class I.

### ASSISTANT
What specific actions have you taken to assess and document the potential classification of GlucoCare under MDR Rule 11, and how do these actions align with MDR Annex I, Section 2.3 (classification of devices) and MDR Annex II, Part B, Section 2.4 (risk management)? [P2.D4]

### USER
We're CE-marked Class I today under the legacy MDD and we've assumed Rule 11 keeps us in Class I, but I'll admit it might bump to IIa under MDR. My read is that we just log and display, with no dose recommendations or automation, so it's borderline.

### ASSISTANT
What specific documentation have you prepared to support your current classification as a Class I device under MDR Rule 11, and how does this documentation address the criteria in MDR Annex I, Section 2.3 (classification of devices) and MDR Annex II, Part B, Section 2.4 (risk management)? [P2.D4]

### USER
Class I MDD legacy, currently going through MDR transition. We've assumed Rule 11 still puts us in Class I but it might bump to IIa.

### ASSISTANT
What specific risk management activities have you conducted to evaluate whether GlucoCare meets the criteria for Class IIa under MDR Rule 11, and how do these activities align with MDR Annex II, Part B, Section 2.4 (risk management) and MDR Annex I, Section 2.3 (classification of devices)? [P2.D4]

### USER
We keep the technical documentation expected for a Class I device and we ran a 6-month beta with 80 patients at a Zürich clinic. We don't yet have a full clinical evaluation report or a IIa-grade lifecycle and risk-management file, because that wasn't required at Class I.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Report for GlucoCare (Class I MDD, transitioning to MDR)**

---

### **High Severity Risks (P1)**

**[P1.D1]** *Data Security & Privacy Compliance*  
- **Risk**: Data is stored on devices and in EU AWS, but no formal threat model, penetration testing, or documented DPIA.  
- **Mitigation**: Conduct a GDPR-compliant DPIA (Article 30), implement ISO/IEC 27001-certified encryption, and document all data processing activities.  
- **Regulation**: GDPR Article 30, ISO/IEC 27001, MDR Annex II, Part B, Section 2.1.

**[P1.D2]** *Data Transfer to Switzerland*  
- **Risk**: Data flows to Switzerland without documented SCCs or updated adequacy assessments.  
- **Mitigation**: Document data transfer agreements under GDPR Article 44 and Article 30, and update compliance documentation.  
- **Regulation**: GDPR Article 44, Article 30.

**[P1.D3]** *Post-Market Surveillance (PMS) & Risk Management*  
- **Risk**: Current PMS is inadequate for Class IIa; no full clinical evaluation report or lifecycle risk management file.  
- **Mitigation**: Engage a Notified Body for Class IIa classification, update risk management documentation per MDR Annex II, and align PMS with MDR Annex I, Section 4.1.  
- **Regulation**: MDR Annex I, Section 4.1; MDR Annex II, Part B, Section 2.4.

---

### **Medium Severity Risks (P2)**

**[P2.D3]** *Data Minimization & PDF Exports*  
- **Risk**: PDF exports could include sensitive data (e.g., HbA1c) if not strictly controlled.  
- **Mitigation**: Implement data minimization controls in PDF exports, align with GDPR Article 9 and MDR Annex II, Part B, Section 2.2.  
- **Regulation**: GDPR Article 9, MDR Annex II, Part B, Section 2.2.

**[P2.D4]** *Classification Uncertainty*  
- **Risk**: Uncertainty around MDR Rule 11 classification (Class I vs. IIa) could lead to regulatory non-compliance.  
- **Mitigation**: Prepare documentation to support current Class I status and evaluate IIa criteria, aligning with MDR Annex I, Section 2.3.  
- **Regulation**: MDR Annex I, Section 2.3.

**[P2.D5]** *Documentation & Compliance Gaps*  
- **Risk**: No formal clinical evaluation report, no DPIA, no DPO, and no SCCs for Switzerland.  
- **Mitigation**: Document all processing activities, appoint a DPO, and draft SCCs for data transfers.  
- **Regulation**: GDPR Article 30, Article 37, MDR Annex II, Part B, Section 2.4.

---

### **Low Severity Risks (P3)**

**[P3.D6]** *User Consent & Data Retention*  
- **Risk**: No explicit consent documentation for Article 9 data (e.g., HbA1c).  
- **Mitigation**: Document explicit consent for special category data and ensure data is deleted within 30 days.  
- **Regulation**: GDPR Article 9, Article 13, Article 17.

**[P3.D7]** *User Awareness & Training*  
- **Risk**: No documented user training or awareness on data privacy and app usage.  
- **Mitigation**: Develop user guides and training materials on data privacy and app features.  
- **Regulation**: GDPR Article 13, Article 30.

---

### **Dimensions Not Covered**

- **[P4.D8]** *Ethical Use & Bias*  
- **[P4.D9]** *Accessibility & Usability*  
- **[P4.D10]** *Transparency & Explainability*  
- **[P4.D11]** *Societal Impact*  
- **[P4.D12]** *Data Sovereignty & Jurisdiction*  
- **[P4.D13]** *User Empowerment & Control*  
- **[P4.D14]** *Environmental Impact*  

---

**Next Steps**:  
- Engage a Notified Body for MDR Rule 11 classification.  
- Conduct a full DPIA and document all data processing activities.  
- Update data transfer agreements for Switzerland.  
- Develop a full clinical evaluation report and lifecycle risk management file for potential IIa classification.  
- Document user consent and data retention policies.  

Let me know if you’d like a

Now produce the JSON judgement object.